Hormone Therapy’s Boxed Warnings Are Changing: What Women Should Know in 2026

For more than 20 years, menopausal hormone therapy has carried one of the strongest warnings the FDA uses: a “boxed warning” about heart disease, stroke, breast cancer, and dementia. That is now changing. In November 2025, the FDA announced that it would remove most of these warnings, and the first updated labels were approved in February 2026.

If you are going through menopause, you may be wondering what this means. Is hormone therapy now safe for everyone? Should you reconsider a treatment you once ruled out? Here is a clear look at what changed, what didn’t, and how to think about your own choices.

Why the Warnings Were There in the First Place

In 2002, a large study called the Women’s Health Initiative (WHI) stopped part of its hormone therapy research early. Women taking a combination of estrogen and a progestin had higher rates of breast cancer, heart disease, stroke, and blood clots in the lungs than women taking a placebo. The results made headlines around the world.

In response, the FDA began adding class-wide warnings to hormone therapy products in 2003. Those warnings applied to all estrogen products in the same way, regardless of a woman’s age, the type of hormone, or how it was taken. Hormone therapy use dropped sharply, and many women stopped considering it at all.

What Researchers Learned Later

Over the following years, researchers took a closer look at the WHI data. They found that many of the women studied were years past menopause and older than the women who usually seek treatment for hot flashes. When researchers looked at women who started hormone therapy closer to menopause, the picture was different.

Today, The Menopause Society’s position is that for healthy women younger than 60, or within 10 years of menopause, the benefits of hormone therapy generally outweigh the risks for treating bothersome hot flashes and preventing bone loss. For women who start later, the balance appears less favorable.

What Changed in 2025 and 2026

After reviewing the scientific literature and holding an expert panel, the FDA made several changes:

• Boxed warnings about cardiovascular disease, breast cancer, and probable dementia are being removed. These risks are still described in the product labeling. They just no longer appear in a boxed warning.
• Low-dose vaginal estrogen is included. The Menopause Society supported removing the warning from these products, which are used for vaginal dryness and related symptoms and release only small amounts of estrogen into the bloodstream.
• Labels now emphasize timing. Updated labels for systemic hormone therapy include information about starting treatment within 10 years of menopause or before age 60.
• The “lowest dose for the shortest time” recommendation was removed, reflecting a move toward individualized care.

What Did Not Change

This part matters just as much.

One boxed warning remains. Estrogen taken on its own, without a progestogen, can increase the risk of endometrial cancer in women who still have a uterus. That warning stays, because adding a progestogen reduces this risk.

The risks themselves did not disappear. Hormone therapy can still increase the risk of blood clots and stroke for some women, and combined estrogen and progestogen therapy is associated with a higher risk of breast cancer, especially with longer use. The label change is about how risk is communicated, not a finding that the risks are gone.

Your personal history still matters. Women with a history of breast cancer, blood clots, stroke, or heart attack, or with unexplained vaginal bleeding, generally should not use systemic estrogen.

Why Your Product’s Label May Still Look the Same

The updates are happening one product at a time. At the FDA’s request, 29 drug companies submitted proposed label changes, and the first six products received approved updates in February 2026. Other products, including many generic versions, may still show the older boxed warning until their updates are approved.

If your prescription still carries the old warning, that does not mean it is riskier than a product that has already been updated. The FDA keeps a public list of hormone therapy products with updated prescribing information.

Is Hormone Therapy Right for You?

There is no single answer. Hormone therapy remains the most effective treatment for hot flashes and night sweats, and it also helps with vaginal symptoms and protects bone. But whether it fits you depends on your age, how long it has been since your final period, your symptoms, and your personal and family health history.

If you are considering hormone therapy, or reconsidering it, these questions can help guide the conversation with your healthcare professional:

• How much do my symptoms affect my sleep, work, and daily life?
• How many years has it been since my final period?
• Do I have a personal or family history of breast cancer, blood clots, stroke, or heart disease?
• Would a patch or gel be a better fit for me than a pill?
• If I have a uterus, how will my uterine lining be protected?
• What non-hormonal options might work for me?
• How often should we reassess my treatment?

If hormone therapy isn’t right for you, you have other options. These include FDA-approved non-hormonal medications, certain antidepressants, and behavioral approaches such as cognitive behavioral therapy and clinical hypnosis.

The Bottom Line

The FDA’s labeling changes reflect a more detailed understanding of hormone therapy than we had two decades ago. For many women, they may make it easier to have an open, informed conversation about treatment. But the best choice is still a personal one, made together with a healthcare professional who knows your full health history.

Want to Learn More?

Our ebook, Understanding Menopause: A Complete Guide to Perimenopause, Symptoms, Treatment Options, and Lifelong Health, explains hormone therapy, non-hormonal treatments, and long-term health in detail, with research last verified in September 2026. Learn more at www.apextome.com.

Sources

• US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products (February 12, 2026).
• US Food and Drug Administration. Menopausal hormone therapies with updated prescribing information.
• The Menopause Society. The 2022 hormone therapy position statement. Menopause, 2022.
• The Menopause Society. Comments on the FDA announcement on hormone therapy (2025).
• Writing Group for the Women’s Health Initiative Investigators. JAMA, 2002.

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional about your health and treatment decisions. Information is current as of September 2026 and may change.

---